Bio­Marin sub­mits NDA for con­tro­ver­sial achon­dropla­sia drug; Cell and gene ther­a­py boom sparks €49M buy­out

Bio­Marin is plow­ing ahead with its achon­dropla­sia can­di­date, sub­mit­ting an NDA to the FDA for vosori­tide Thurs­day af­ter­noon.

If ap­proved, the drug would be a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER